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INTRODUCTION 
 Prosthetic valve thrombosis (PVT) is a serious and the most 
dangerous complication, the incidence varies in various parts of the 
world. The risk factors are multifactorial. The technique of surgical valve 
replacement introduced in earlier 1960s markedly changed the prognosis 
of patients having valvular heart disease. Around 300 000 valve 
replacements are done all over the world each year with both mechanical 
as well as bio prosthetic valves. In spite of substantial developments in 
surgical techniques and the design of prosthetic valve over the past 
decades, replacements of valves have not provided a cure. The durability, 
hemodynamics and thrombogenicity of the prosthetic valves affect the 
prognostic outcome of valvular heart disease patients who undergo 
replacement of valve. Most of the complications related to prosthetic 
valves can be prevented by optimal selection of prosthesis and its follow 
up management. The ideal prosthetic valve should be having the same 
characteristics of the native valve with good hemodynamics, extensive 
durability, resistance to thrombosis, and suitable implantability. But, 
such ideal prosthesis has not been so far found, and the 
presently available prosthetic valves have many limitations. The 
treatment strategies such as surgery and fibrinolysis remain the main stay. 
Trans thoracic echocardiography (TTE), Transesophageal 
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echocardiography (TEE) and sometimes fluoroscopy aids in diagnosis. 
Prosthetic valve thrombosis is diagnosed when any thrombus, in the 
absence of infection, adherent over the operated valve or near it, 
obstructing part of the blood flow or interfering  function of the valve.. 
TEE has limitation to distinguish between pannus and infected 
vegetations from thrombi. In such instances, clinical aspects are helpful. 
The incidence of PVT is estimated to be 0·1 to 6% per patient-year, of 
which aortic PVT -0·2% per patient-year, mitral PVT – 1.8% per patient-
year. But the incidence should be higher, as TTE and TEE reveals almost 
all cases and of which half are asymptomatic. Various therapeutic 
modalities are recommended for PVT. Surgical treatment is indicated for 
69%, according to their NYHA class and emergency situation. 
Thrombolysis is also recommended as a treatment option, showing more 
than 80% success and fewer complications. There are no absolute 
contraindications besides classical contraindications such as early 
postoperative period large thrombi, pregnancy for thrombolysis. 
Streptokinase protocols have been used. Heparin can also be a primary 
treatment option for nonobstructive PVT, but fibrinolysis is more 
superior. If the size of the thrombi attached to the leaflets is larger, 
heparin is not helpful. During heparin therapy TEE should be done, as 
there may be increase in the size of thrombi and can cause obstruction. 
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Thrombolysis, if there are no contraindications can be recommended as 
first-line of treatment. Surgery is recommended for patients for whom 
there is contraindication for thrombolysis or where it’s deemed to be 
ineffective. Prosthetic valve thrombosis (PVT) can endanger the life for 
which therapeutic options remain controversial. It may be salient to 
review the definitions,  tools for diagnosis and their limitations, the 
epidemiology of PVT before comparing, discussing the different 
therapeutic modalities that are available for treatment of  this condition. 
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AIMS AND OBJECTIVES 
  
 
          To study the incidence, risk factors of patients presenting with 
prosthetic valve thrombosis. 
 To study the treatment strategies of patients presenting with 
prosthetic valve thrombosis. 
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REVIEW OF LITERATURE 
 Prosthetic valve thrombosis (PVT) could be a rare however a 
dangerous complication of prosthetic valve implantation. The morbidity 
and mortality of this disease is high and needs speedy diagnostic analysis. 
However, diagnosis is often difficult, primarily as a result of varied 
presentations and therefore the amount of valvular obstruction. 
Transthoracic echocardiography (TTE) and transesophageal 
echocardiography (TEE) and cinefluroscopy for mechanical valves are 
the common diagnostic tools. Though surgery is the preferred treatment 
in obstructive PVT still other options are available. The various treatment 
options offered for PVT are primarily based on the presence of 
obstruction of the valve orifice, by location of the valve (right or left 
sided), and clinical mode of presentation. Therefore, treatment of left-
sided PVT can be different from right-sided PVT or non obstructive PVT. 
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Figure showing various types of prosthetic valves 
 
EPIDEMIOLOGY: 
 Thromboembolism, are frequent which occur at an incidence of 
0.8–6.1% patient years [1]. PVT which are non obstructive could be a 
comparatively frequent finding in the post operative periods [2]. Though 
these are non-obstructive small thrombi, they emphasize the treatment 
with anticoagulants in the post operative periods [3].  Bioprosthetic valve 
thrombosis could be a rare phenomenon compared to mechanical valves 
[4]. PVT of bioprosthesis is sometimes diagnosed within the early post 
operative period, as suture zone endothelialisation isn't nonetheless 
complete. Hence, anticoagulants are advised for the first three months 
after bioprosthetic valve implantation, especially for prostheses at mitral 
position. 
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PHYSIOPATHOLOGY: 
 Based on Virchow’s triad, the factors which predisposes to 
thrombosis are classed into hemodynamic, endothelial and haemostatic 
elements [5]. Biocompatibility of the prosthetic device is represented by 
endothelial factors and interaction between the prosthetic device and the 
suture zone. Endothelialisation and tissue cicatrisation characteristically 
need a couple of weeks to be completed. Haemodynamic factors 
represents haemodynamic characteristics of the prosthetic device, and 
cardiac hemodynamics overall. Though the profile of recent generation 
bileaflet mechanical valves is basically superior thereto of previous 
generation prosthetic valves (and so related to a lower incidence of 
thromboembolism), flow turbulence at localised regions will still develop 
and result in stasis and formation of thrombus. Additionally, the 
prosthetic device location is a crucial factor in thrombogenicity. Tricuspid 
mechanical valve obstruction is twenty times frequent than PVT of left 
side. 
 Also PVT in mitral location is more frequent than occlusion of 
prosthetic device in aortic position for haemodynamic reasons. 
Thrombosis, significantly in low flow states or decreased cardiac output 
situations is also due to hemodynamic reasons. The adequacy of 
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anticoagulant treatment involves haemostatic factors. Hence, the 
immediate post operative period represents a specific challenge with the 
necessity to balance the danger of over anticoagulation and associated 
bleeding complications with under-anticoagulation and thromboembolic 
complication.[6] Equally, stopping of anticoagulants for non-cardiac 
surgery and pregnancy are significant risky situations [7,8]. Pathology 
Although PVT presents as acute thrombosis, its mostly subacute or 
chronic development. Apparently, recent literature have shown the higher 
reports of pannus formation (46–76% of cases), that is additionally 
related to the risk of thrombus formation. Pannus formation is sometimes 
discovered near suture and may be situated on either side of the prosthetic 
device, degrees of evidence of obstruction [9]. Lastly, obstruction may 
result from vegetation during endocarditis of prosthetic valve. 
How to diagnose:  
Clinical scenario: 
 The clinical presentation is extremely variable, based upon if the 
obstruction is present or not. PVT with severe obstruction is usually 
presents as heart failure, whereas PVT which is non obstructive is 
commonly present incidentally or embolism. Obstruction which is partial 
will present as breathlessness or embolic phenomenon and infrequently 
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fever. Diagnostic blood cultures ought to be performed in the presence of 
fever to diagnose infectious carditis. 
Biochemical tests: 
 Traditional markers of inflammation and levels of anticoagulation 
are done through biochemical analysis. D-dimer levels could also be 
elevated. Meticulous clinical examination ought to be performed, to look 
for muffling of valvular sounds, appearance of new murmur which can be 
stenotic or regurgitant.  
Fluoroscopy: 
 All mechanical prosthetic valves offered are radiopaque, 
cinefluoroscopy is an important diagnostic tool for analysis of PVT. 
However, this method is not useful in differentiating pannus from 
thrombus. Hence, further diagnostic work up should be done [10].  
Trans thoracic echocardiography:  
 By TTE, prosthetic device can be directly visualised and measure 
transvalvular gradients. It is a vital part in diagnosis. A customary 
complete examination ought to be performed, with important attention 
given to measuring transvalvular flow, gradient, and visualization of 
prosthetic device [11]. Using colour Doppler, abnormalities in the flow 
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across prosthesis or central regurgitation, which indicates valve closure of 
the valve, are often discovered. Transprosthetic gradients and effective 
orifice area (EOA) are measured using continuous wave Doppler. 
Measurement of cardiac output and pulmonary artery pressure should be 
done. Direct signs of PVT are abnormal mobile prosthetic device or 
thrombus at or near the valve apparatus visualisation. For mitral 
prostheses, A mean gradient >8 millimetre of mercury and an EOA of 
<1.3 cm2 suggests PVT. For prostheses in aortic position, PVT criteria are 
a mean gradient >45 millimetre of mercury and an obstruction index 
<0.25. In the event of prosthetic aortic valve which are smaller in size, 
identification is tough taking in to the fact that they normally have 
elevated gradients, owing to turbulent flow across the orifice which is 
small and causing patient–prosthesis match (PPM) [12,13]. 
 “Silent Doppler PVT” is the term used to specify during low 
cardiac output situation where transvalvular gradients can be normal and 
still there may be obstruction of prosthesis [14]. 
Trans esophageal echocardiography: 
 In cases of large PVT, TEE may not be required. In most of the 
cases, TEE can offer vital further diagnostic info, which can additionally 
guide treatment [15, 16]. Direct signs of PVT are immobility or reduced 
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leaflet quality, and therefore the thrombus on either facet of the prosthetic 
device, with or while not obstruction. 
 A fibrous pannus which is usually in annular location needs to be 
differentiated from thrombi. Formation of pannus is more on aortic rather 
than prostheses on mitral position. Indirect signs of PVT by TEE are 
usually the non visualisation of the physiological prosthetic device 
regurgitation, the visualization of central regurgitation, and left atrial 
spontaneous contrasts in echocardiography. 
 TEE also has some major limitations: prostheses at aortic location 
are difficult to be evaluated than prostheses at mitral location, and as also 
the ventricular side of the prosthesis at mitral location. It is additionally 
vital to differentiate smaller thrombus from strands or sutures. Strands are 
the protein structures, showing as fine usually <1 mm, filiform, mobile 
echos of differential length (approximately ten millimetre), and 
frequently discovered on the atrial part of mitral prostheses. Though the 
ideal nature of those strands still unknown, literature states that there is 
no significant risk of embolism. 
 Finally, it is to be emphasized the vital role of TEE in deciding 
treatment methods. For PVT in the left sided valves, surgery is preferred 
for larger thrombus, as thrombolysis increases the risk of embolism. The 
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PRO-TEE register suggest that a thrombus with a size of >.0.8 cm2 and a 
previous history of cerebrovascular event as the significant factors for the 
anticipation of complications of fibrinolysis [17]. In non-obstructive 
PVT, the main stay of therapy is optimal medical treatment, unless there 
is a very larger or freely mobile thrombus. TEE is additionally useful in 
differentiating a pannus from thrombus, and in deciding size of the 
thrombus accurately. Thrombosis of a bioprosthetic valves encompasses a 
similar clinical presentation thereto of mechanical PVT. In cases of PVT, 
TTE can demonstrate abnormal transvalvular gradients. TEE is more 
sensitive than TTE for the identification of thrombosis of bioprosthesis.  
Figure showing various disease process affecting prosthetic valves 
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TREATMENT: 
 Once PVT is diagnosed, treatment modalities must be decided such 
as surgery in the form of thrombectomy or valve replacement, 
thrombolysis, heparin, or anticoagulation dose adjustments or 
antiplatelets. Treatments are often optimized based on the presence of 
obstruction and prosthetic device location. The prosthetic device type 
doesn't impact treatment options, because the selection between surgical 
and medical treatment depends on location of the prosthesis, size of the 
thrombus and clinical situation. The introduction of TEE has paved the 
way for the best treatment modality for non-obstructive PVT. 
Treatment is often done as per the size of the thrombus: 
1.  For non-obstructive thrombi of size >5mm, surgery is indicated in 
cases of medical management failure (heparin), especially when 
the thrombus is large, pedunculated and mobile [2, 6, 18].  
2.  For smaller non-obstructive thrombi of <5mmi, preferred strategy 
is medical treatment. Treatment with heparin is continued for seven 
days with repeat TEE to gauge therapeutic effectiveness, or 
adjustment of anticoagulant medication and introduction of aspirin 
at a lower dose (100 mg). thrombolysis can be given successfully 
for smaller nonobstructive thrombi, however with a risk of 
embolism. 
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 Obstruction of a mechanical prosthetic device needs treatment 
aggressively (surgery or thrombolysis), as there is always sub therapeutic 
anticoagulation levels in these patients.  
 There are only few guidelines in the literature regarding PVT 
management (level two recommendations). American of Cardiology/ 
American Heart Association recommend surgery as the treatment of 
choice for left-sided PVT [19]. Thrombolysis is recommended for 
clinically and hemodynamically unstable patients (NYHA III or IV), with 
high surgical risk or contraindications to surgery. It can also be 
recommended for hemodynamically stable patients with functional class 
of I, II and a smaller thrombus following heparin treatment failure.  
Right-sided PVT:  
 Mechanical prosthetic valves are seldom implanted in the right side 
of heart, primarily as a result of their increased thrombogenicity. 
Obstruction of pulmonic or tricuspid prosthetic device is a situation for 
thrombolysis [20]. Surgery is indicated for right sided PVT in cases of 
failure of thrombolysis. 
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Left-sided PVT: 
 Surgery is the treatment of choice for left sided PVT, with 
thrombolysis reserved for exceptional situation [21, 22, 23]. 
Traditionally, surgery was considered as a high risk, but with the recent 
advancement in the operative procedure and anaesthesia, prognosis has 
been considerably improved. . Surgery can be replacement of the valve or 
thrombectomy. Thrombolysis was introduced as a reasonable alternative 
in the early 1970s. A recent review by Lengyel et al found thrombolysis 
to be efficacious in 82% cases, however with an associated 10% 
morbidity and a 12.5% risk of emboli [24]. Thus because of this high 
complication rate thrombolysis is recommended as a second line therapy. 
A simple algorithmic program for the management of PVT is as follows  
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Figure shows algorithm for treatment of PVT 
 
Fibrinolytic treatment protocols: 
 There are no accepted guidelines regarding the most effective 
thrombolytic programme. Two different strategies are suggested. In 
patients with unstable hemodynamics, ‘‘rescue’’ thrombolysis is 
preferred employing a ‘‘short protocol’’ with either: 1. Streptokinase 
1500 000 U in sixty minutes while not heparin. 2. Recombinant tissue 
plasminogen activator (rtPA) ten mg bolus + ninety mg in ninety minutes. 
In patients with stable hemodynamics, another longer term strategy is 
commonly preferred: Streptokinase 500000 IU in 20 minutes followed by 
 17 
150000 IU over 48 hours without heparin or Urokinase 4500 U/kg/h over 
twelve hours, or 2000 U/kg/h + heparin over twenty four hours. 
rtPA ten mg bolus, followed by 50mg throughout the first one hour, 
twenty mg in the second hour and twenty mg in the third hour. Another 
thrombolytic agent can be used in case of failure of primary agent. 
Embolic complication is the dreaded risk of thrombolytic agents. TTE has 
a vital role in selection of patient for ultimate thrombolytic treatment. 
Thrombolysis has greater effectiveness for recent smaller thrombi 
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SUBJECTS AND METHODOLOGY 
 48 patients who were admitted in the department of cardiology, 
Rajiv Gandhi government general hospital, Chennai, with signs and 
symptoms of prosthetic valve thrombosis were included in the study. 
These patients had prosthetic valve implanted for severe rheumatic heart 
disease.  
Inclusion 
criteria 
Patients who are diagnosed to have prosthetic valve 
thrombosis. 
 
Exclusion 
criteria 
Patients with prosthetic valves but not fulfilling the 
criteria for prosthetic valve thrombosis. Not willing to 
sign consent form 
Investigation 
details 
1) Mode of clinical presentation. 
2) ECG, Echocardiography(Trans thoracic and Trans 
esophageal) 
3) Fluoroscopy  
 
 
 The incidence and risk factor, clinical profile of patients who are 
presenting with prosthetic valve thrombosis and their treatment strategies 
were analysed.  They were on anticoagulants and were in follow up.  
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Patients with prosthetic valves and not fulfilling the criteria for PVT and 
those not willing to sign the consent form were excluded from the study.  
 Meticulous history was taken and risk factors predisposing to the 
PVT were recorded. Clinical examination was done and various 
presentation pattern of PVT were analysed. Investigational workup with 
electrocardiogram, echocardiography with both Trans Thoracic and Trans 
Esophageal mode were done in all patients to diagnose PVT. In all cases 
fluoroscopy was also done to both diagnose and to assess the treatment 
success. Preoperative clinical data, initial valve procedure and 
complications if any were recorded. Several factors such as the risk 
factors for PVT development, including sex, aortic versus mitral position, 
and single versus double-valve replacement, time duration since the valve 
replacement will be analyzed. 
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Clinical criteria used to suspect PVT: 
 Muffling or absence of prosthetic valve sounds was taken as an 
indirect sign of PVT.  
Figure showing the normal and abnormal auscultatory findings in 
patients with prosthetic valves 
 
Echo criteria for diagnosing PVT: 
 By Philips HD 7 echo machine two-dimensional and Doppler 
echocardiographic studies were done; the system has 3.5 and 2.5 
transducers (2- dimensional echocardiography), and 2.5 MHz transducers 
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for pulsed and continuous wave Doppler. A thorough 2-D 
echocardiographic examination was performed to view the prosthesis in 
many cross-sectional views. Continuous wave Doppler mode was used to 
measure the flow across the prosthetic valves. Peak pressure gradients 
were obtained from peak velocities by modified Bernoulli equation: P=4 
xV2; mean pressure gradients were obtained with the software in the echo 
machine. Pressure half-time method was used to calculate the effective 
mitral orifice area. 
 TEE was done with 5 MHz multiplane probes. Criteria for mitral 
PVT were: evidence of thrombus with or without altered mobility of the 
disk(s) and pathological regurgitation through the prosthesis. Thrombus 
was defined as a “distinct mass of abnormal echoes attached to the 
prosthesis and clearly seen throughout the cardiac cycle”. 
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Echocardiographic criteria to diagnose mitral prosthetic valve 
obstruction: 
 Normal  Possible  Significant  
Peak velocity  <1.9  1.9-2.5  ≥ 2.5  
Mean gradient  
(mm Hg)  
≤ 5  6-10  >10  
VTI prmv/VTI LVO  <2.2  2.2-2.5  >2,5  
EOA (cm2)  ≥ 2  1-2  <1  
PHT (ms)  <130  130-200  >200  
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Echocardiographic criteria to diagnose aortic valve PVT: 
Peak velocity  Normal  Possible  significant  
Peak velocity  <3  3-4  >4  
Mean gradient  <20  20-35  >35  
DVI  ≥ 0.30  0.29-0.25  <0.25  
EOA (cm2)  >1.2  1.2-0.8  <0.8  
Contour of jet  Triangular early 
peaking  
Triangular to 
intermediate  
Rounded 
symmetrical  
AT (ms)  <80  80-100  >100  
 
 A diagnosis of pannus formation was made when fixed, bright 
echodense structures, sometimes containing focal calcific deposits, were 
present primarily along the valve ring with extension into the valve 
orifice. 
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Fluoroscopic criteria for diagnosing PVT: 
 Fluoroscopic criteria for prosthetic valve obstruction were: 
persistent restriction of leaflet(s) motion with calculated opening angle 
greater than the mean value (_2SD) obtained in a reference group of 
patients with normally functioning valve of the same type. Opening and 
closing angles were defined as the distance between the 2 leaflets in the 
fully open and closed position.  
Figure showing opening and closing angle measurement by 
fluoroscopy 
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Echo criteria for successful thrombolysis: 
 Patients with obstructive thrombus, and those with nonobstructive 
thrombus, who either had a history of embolization or had a large 
thrombus mass (>10 mm base diameter and/or >5 mm mobile segment 
length) were accepted as candidates for thrombolysis. Patients with large 
thrombus were not excluded. Thrombolytic treatment was contraindicated 
in patients with bleeding tendency and in those with expanding or 
hemorrhagic cerebral infarcts. Streptokinase (SK) was the agent used in 
all patients who were eligible for thrombolysis.  Loading dose of SK was 
used. 2, 50,000 units was used as a loading dose followed by 1, 00,000 
units per hour for 24-48 hours. Heparin as an infusion given after 
thrombolysis and overlapped with Acenocoumarol till the target INR 
reached >2.5.The response to thrombolytic treatment was defined as a 
complete success “when significant narrowing of the valve (based on 
hemodynamic measurements) was no longer present and a >75% 
reduction in largest diameter of the thrombus mass was achieved. For 
nonobstructive thrombi, a reduction by>75% in thrombus diameter or 
complete lysis of the mobile portion of the thrombus” was required as 
criteria for complete success. Clinically reduction in the severity of 
functional class, return of valve click sounds, echocardiographically by 
reduction of gradient and by fluoroscopy  return of normal disc motion 
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.The positive responses that were less than “completely successful” were 
accepted as partial success. Treatment response was graded incomplete if 
there is a significant clinical improvement without complete recovery of 
disc or leaflet motion on fluoroscopy and/or TTE and graded as failure if 
there is no clinical improvement, in many cases associated with death or 
complications. 
 Surgery was done for the patients with large thrombi, mobile 
thrombi, shock, high risk for thrombolysis such as history of hemorrhagic 
stroke, active internal bleeding and severe hypertension at presentation 
(>200/120mmHg).  
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OBSERVATIONS AND RESULTS  
 48 patients were admitted with signs and symptoms of prosthetic 
valve thrombosis. Out of which 35 patients were males and 13 were 
females with the age ranging from 25-48 years. Overall 38 patients 
(males: 30, females: 8) were from rural areas and the remaining (males:5, 
females:5) were from semi urban areas. 30 patients (males: 20, females: 
10) had prosthetic valve implanted in mitral position, 17 patients (males: 
14, females: 3) had aortic valve prosthesis and one male patient had 
double value (both mitral and aortic) replacement. 35 patients (males: 26, 
females: 9) presented with PVT within one year of implantation and the 
remaining patients (males: 9, females: 4) presented 1-3years since their 
valve replacement. On analysing the previous records, only 28 people 
were on regular follow up of once in a month and the remaining 20 
patients were on less than 2 follow ups after their surgery. 
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Patients Male Female 
48 35 13 
 
Age range 25 – 48 years 
 
Presentation of acute thrombotic 
occlusion 
Male Female 
Less than 1 year 26 9 
1 year to 3 years 9 4 
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Patient’s profile Male Female 
Rural 30 8 
Semi urban 5 5 
 
Follow ups No of patients 
Regular 28 
Only 2 follow ups 20 
 
Valves replaced Males Females 
Mitral 20 10 
Aortic 14 3 
Double valve replacement(mitral 
and aortic) 
1 0 
 
Co morbid conditions No of patients 
Diabetes mellitus 1 
Dyslipidemia 3 
Tuberculosis 2 
 
 30 
 Co morbid conditions like dyslipidemia (3 patients), diabetes 
mellitus (1 patient), and tuberculosis (2 patients) were present. 
Acenocoumarol was the anticoagulant used for the patients. 38 patients 
(males: 28, females: 10) were on regular anticoagulant medications. 10 
patients were on irregular medications. Various pattern of presentation 
were noted such as muffled clicks (48 patients), pulmonary edema (36 
patients), class IV symptoms (43 patients), new onset off murmur (15 
patients), chest pain (24 patients), hypotension (38 patients), atrial 
fibrillation (12 patients), fever (3 patients) 
Intake of anti 
coagulants 
Male Female 
INR 2.5 AND Above 8 2 
INR less than 2.5 27 11 
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Pattern of presentation Male Female 
Fever 2 1 
Class 4 symptoms 32 11 
Chest pain 14 10 
Pulmonary oedema 28 8 
Hypotension 30 8 
New onset murmur 10 5 
Atrial fibrillation 2 10 
Muffled clicks 35 13 
 
Complications Male Female 
Fatal bleeding 2 1 
Cerebral embolism 2 0 
 
 INR <2.5 predisposes to thrombosis. In our study 38 patients had 
INR <2.5, remaining 10 patients had valve thrombosis despite INR >2.5. 
 Out of 48 patients 34 (70.8%) patients underwent thrombolysis 
with Streptokinase. 14 (10 mitral and 4 aortic) patients underwent surgery 
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(29.2%). Thrombolysis was successful with return of full leaflet mobility 
in 22 patients (64.7%). Partial return of leaflet mobility in 7 patients 
(20.6%). 5 patients died of complications (14.7%). 60% (12/20) of 
patients had complete success following thrombolysis of mitral valve 
prosthesis, 77% (10/13) of patients had complete success following 
thrombolysis in aortic valve prosthesis. One patient with double valve 
replacement had thrombosis of mitral valve- underwent successful 
thrombolysis. Total mortality in our study is 7 (14.6%). 3 patients died of 
fatal bleeding, 2 patients died of Cerebral embolism and 2 patients out of 
14 patients who underwent surgery died. 
Figure shows gender profile 
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Figure shows timing of occurrence of valve thrombus following valve 
implantation 
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Figure showing follow up course of the patients after valve 
replacement 
 
 
 
 
58.3% 
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Figure shows level of anticoagulation in the patients 
 
Figure shows incidence of thrombosis according to the valve location 
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Figure shows the various causes of prosthetic valve thrombosis 
 
Figure shows clinical profile of the prosthetic valve thrombosis 
patients 
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Figure shows percentage of patients with various levels of success of 
thrombolysis 
 
Figure shows successful thrombolysis according to location of 
thrombus: 
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Figure shows echocardiographic parastrenal long axis view of 
thrombus in the mitral prosthetic valve 
 
Figure shows echocardiographic parastrenal long axis view with 
colour flow doppler of thrombus in the mitral prosthetic 
valve
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Figure shows echocardiographic parastrenal short axis view of 
thrombus in the mitral prosthetic valve 
 
Figure shows increased flow gradient across mitral valve 
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Figure shows severe tricuspid regurgitation and severe pulmonary 
hypertension 
 
Figures showing echocardiography of opening of mitral prosthetic 
leaflet following successful thrombolysis 
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Figures showing decrement in gradients following thrombolysis  
at 24 hours 
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Figures showing decrement in gradients following  
thrombolysis at 48 hours 
 
Fluoroscopic images showing opening of the prosthetic valve leaflets 
following thrombolysis 
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Figure shows reduction in tricuspid regurgitation and subsequent 
pulmonary hypertension 
 
 
 45 
DISCUSSION 
 PVT is a life threatening situation. Prompt earlier diagnosis 
followed by rapid treatment will save the life. Management of severe 
rheumatic heart disease by prosthetic valve implantation does not mean 
the patient is cured. With the implantation of artificial valves, a 
disciplined protocol for follow up and maintenance of anticoagulation 
levels are the important task. With more than 3, 00,000 valve 
replacements done worldwide there arise a new group of patients called 
prosthetic valvular heart disease patients. These patients has to be 
managed with high levels of health education about the valves, about the 
anticoagulants, about the necessity of maintaining adequate INR levels 
and need for regular follow up, food habits etc. 
 In our study, all the 48 patients had bileaflet mechanical valve in 
various locations such as mitral, aortic. Majority of our patients were 
males and belong to rural areas in our study. Except for co morbid 
conditions such as diabetes, dyslipidemia and tuberculosis in a few 
patients, majority of our patients were free of associated diseases. About 
73% of our patients presented with PVT within one year of valve 
replacement. Thus surgery related issues and post operative care, post 
operative monitoring of anticoagulation, follow up and importance of 
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maintaining INR levels are areas to be intervened. 2 patients had 
pulmonary tuberculosis and were taking anti tuberculosis drugs. Drug 
interaction of acenocoumarol with rifampicin could be a cause for low 
PT/INR in these patients. 
 Clinically all our patients had muffling or absence of prosthetic 
valve sounds. Most of the patients presented with pulmonary edema, class 
IV symptoms and hypotension. About 25% of patients had atrial 
fibrillation at presentation, which were new onset. Thus atrial fibrillation 
could be a predisposing factor. 3 of our patients had fever of high degree 
during presentation. Fever leading to dehydration could also be a 
contributor for PVT. In our study, about 63% of patients with PVT had 
prosthetic valve at mitral location and 35% had aortic prosthetic valve. 
Since prosthetic valve at mitral position is prone to thrombosis, our study 
also confirmed it 
 On analysing the records available with the patients we found that 
about 42% had infrequent follow up. Thus a greater emphasis should be 
placed on educating the patient for the need of follow up. 79% of our 
patients during presentation had INR of <2.5.Thus a major reason for 
PVT in our study is inadequate anticoagulation. Buttard and colleagues10 
found inadequate systemic oral anticoagulation at the time of diagnosis in 
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45%: 27% for medical reasons (surgical intervention, neurologic events, 
or pregnancy) and 17% because of poor patient compliance. This is the 
vital area of care and lot of resources and man power is needed to 
overcome this major factor. Also 21% of our patients presented with PVT 
in spite of their INR being above 2.5 at the time of presentation. The 
probable reasons could be pannus rather than thrombus could be the 
reason for obstructive PVT or the reliability of INR as a measure of 
adequate anticoagulation is not superior. In our study 34 (70.8%) patients 
underwent thrombolysis with Streptokinase. Treatment options were 
decided according to the guidelines. And the thrombolytic therapy was 
given according to the protocols followed by heparin and warfarrin. 
 The recent review of Lengyel et al. of 200 published reports of left-
sided prosthetic heart valve thrombolysis showed an 82% initial success 
rate, an overall thromboembolism rate of 12%, and a mortality rate of 
10%. This consensus conference indicates that FT of left-sided PVT is 
acceptable for critically ill patients in whom surgical intervention carries 
high risk or in patients with contraindications to operation. Several 
studies have examined the role of thrombolysis in the management of 
PVT. Recently, Roudaut and coworkers conducted a retrospective study 
of 110 patients treated with fibrinolytic therapy and concluded that the 
treatment should be reserved for selected patients (those with tricuspid 
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thrombosis, critically ill patients, and patients with contraindications to 
surgical intervention).  
 Thrombolysis was successful with return of full leaflet mobility in 
22 patients (64.7%). Partial return of leaflet mobility in 7 patients 
(20.6%). 5 patients died of complications (14.7%) in our study. When 
analyzed the success of thrombolytic therapy according to valve location 
it has been found that 60% (12/20) had complete success following 
thrombolysis of mitral valve prosthesis and 77% (10/13) complete 
success following thrombolysis in aortic valve prosthesis. One patient 
with double valve replacement had thrombosis of mitral valve- underwent 
successful thrombolysis. So, overall thrombolysis is better treatment 
alternative to surgery in many patients for whom surgery could not be 
performed. 5(about 15%) patients who were in the thrombolysis arm died 
due to bleeding complication (3 patients) and cerebral embolism (2 
patients).  
 14 (10 mitral and 4 aortic) patients underwent surgery (29.2%). 
Surgery was done in the form of simple thrombectomy in 8 patients 
(57%) and valve replacement in remaining 6 patients (43%). 2(14%) 
patients who underwent valve replacement died. 
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Patients with PVT have high mortality. The commonest predisposing 
factors for PVTs are inadequate anticoagulation and poor patient 
compliance. Thus underscoring the need for both patient- and physician- 
oriented education. Thrombolysis is a reasonable and valid alternative 
therapy. Surgical intervention may be needed in many patients with PVT. 
In short regular follow up, periodic monitoring of INR and adjusting it to 
the ideal level and stable diet pattern play important role in preventing 
complications of prosthetic valves. And in today’s world where there is 
excellent communication facilities, patients can be followed up through 
phone where the dose of the patient’s anticoagulants can be modified 
according to the INR levels which they can see in their native place and 
communicate to the doctors through phone. 
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CONCLUSION 
 The incidence of PVT is higher and is about 1.2 per 1000 patient 
years. 
 The major risk factors for PVT observed in our study are 
inadequate anticoagulation, lack of follow up and patient prosthesis 
mismatch. 
 Regarding treatment thrombolysis is a reasonable alternative for 
surgery with nearly 80% success rate. 
 As the rheumatic heart disease is very much prevalent in India, 
prosthetic heart valves implantation rate is increasing every year due to 
high incidence of RHD in India. Inadequate anticoagulation, lack of 
follow up, non compliance, lack of health education continues to be the 
major factors for PVT.  
 Technical and lesion related factors are also important as many 
cases present early after surgery. So, special care should be taken to avoid 
patient prosthetic mismatch.  
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 Clinical recognition of  PVT  still plays a vital role, as subtle signs 
like increase in dyspnea and muffling of clicks may picked up at bedside 
and leads to suspicion of PVT.  
 Diagnostic tools such as echocardiography (TTE, TEE) play a vital 
role in diagnosis of PVT through detection of increased gradients and 
appearance of new regurgitation and visualization of mobility of leaflets.  
 Thrombolytic therapy  can be considered as  an effective initial 
intervention (In spite of being class IIb indication as per AHA).  
 Surgery should be recommended for valve dehiscence, large 
thrombus and for those patients having contraindications to thrombolysis. 
Emergency cardiac surgery cannot be advocated in most due to logistic 
reasons.  
 Patient education & better communication are the best tools for 
prevention of PVT. Physicians need to be aware of various drug 
interactions with anticoagulants such as warfarrin and acenocoumarol. 
 Patients need to be educated about the importance of periodic 
monitoring of INR and adjusting it to the ideal level. They also need to be 
educated about the anticoagulants and to be taught about subtle signs of 
bleeding and early signs of PVT. 
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 Finally, in the era of advancement in communication systems 
patient doctor relation can be improved and will play a crucial role in 
anticoagulation maintenance and thus preventing prosthetic valve 
thrombosis. 
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ABBREVIATIONS 
PVT   - Prosthetic Valve Thrombosis 
ECG   - Electrocardiogram 
TTE   - Trans Thoracic Echocardiogram 
TEE   - Trans Esophageal Echocardiogram 
NYHA  - New York Heart Association 
EOA   - Effective Orifice Area 
ACC/AHA  - American College Of Cardiology/  
    American Heart Association 
rTPA   - Recombinant tissue plasminogen activator 
Mg   - Milligram 
MM   - Millimetre 
IU   - International unit 
OC   - Opening Click 
CC   - Closing Click 
MHz   - Mega Hertz 
VTI PrMV  - Velocity Time Integral Prosthetic Mitral  
    Valve 
VTI LVO  - Velocity Time Integral Left Ventricular   
    Outflow Tract 
PHT   - Pressure Half Time 
AT   - Acceleration Time 
PT/INR  - Prothrombin Time/ International      
                                         Normalised Ratio 
PROFORMA 
Name  
Age   
sex  
Address   
Occupation   
Education   
Type of valve  
Duration since valve implantation  
Clinical parameters  
Pulse rate   
Respiratory rate   
Spo2  
Systolic blood pressure   
Diastolic blood pressure   
Cardiovascular examination  
Heart / prosthetic valve sounds  
Other system examination  
Co morbid conditions   
Diabetes   
Systemic hypertension   
Renal failure  
Tuberculosis   
Malignancies   
HIV  
Heart failure   
Pericardial effusion  
 
 
 
INVESTIGATIONS 
 
Biochemical   
Haemoglobin   
Blood sugar   
Urea   
Serum creatinine   
Lipid profile  
Liver function test  
Prothrombin time/INR  
Peripheral smear  
 Bleeding time  
Clotting time  
  
Electrocardiography   
  
Echocardiography    
Trans thoracic echo  
Trans esophageal echo  
  
Fluoroscopy   
 
 
 
 
